title: Clinical characteristics of patients with solitary pulmonary mass after radical treatment for primary cancers: pulmonary metastasis or second primary lung cancer?
abstract: We identified clinical characteristics of 30 pulmonary metastasis (PM) patients and 29 second primary lung cancer (SPLC) patients with feature of solitary pulmonary mass (SPM) after radical treatment of prior cancers. 6.7% and 44.8% patients presented with centrally located SPM and the median event-free durations were 33 and 72 months in PM and SPLC groups, respectively. PM was more likely to be found in prior cancers with stage III. In conclusion, the location of SPM, the event-free duration and the prior tumor staging were important features for differentiating SPLC from PM among patients with SPM after prior cancers.
authors.affiliation: Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Ge
authors.forename: Hong-Feng
authors.initials: HF
authors.lastname: Gou
authors.forename: Ye
authors.initials: Y
authors.lastname: Chen
authors.forename: Ke
authors.initials: K
authors.lastname: Cheng
authors.forename: Long-Hao
authors.initials: LH
authors.lastname: Li
authors.forename: Hang
authors.initials: H
authors.lastname: Dong
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Feng
authors.initials: F
authors.lastname: Zhao
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Men
authors.forename: Qiu
authors.initials: Q
authors.lastname: Li
authors.forename: Meng
authors.initials: M
authors.lastname: Qiu
authors.forename: Jing-Mei
authors.initials: JM
authors.lastname: Su
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.forename: Feng
authors.initials: F
authors.lastname: Bi
authors.forename: Ji-Yan
authors.initials: JY
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000628:therapy; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy